Mgmt expression correlates with response rate and survival in patients with inoperable glioblastoma (GBM) treated with neoadjuvant temozolomide (TMZ)

被引：0
|
作者：
Barrie, M.
Eudes, N.
Boucard, C.
Metellus, P.
Fuentes, S.
Honoré, S.
Dufour, H.
Figarella-Branger, D.
Chinot, O.
机构：
[1] CHU Timone, Marseille, France
[2] Fac Med Nord, Marseille, France
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 352
页数：1
相关论文
共 50 条
  • [21] NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS (PTS) WITH GLIOBLASTOMA (GBM) (NUTMEG): TRIAL IN PROGRESS
    Khasraw, M.
    McDonald, K.
    Yip, S.
    Verhaak, R. G.
    Heimberger, A. B.
    Hall, M.
    Barnes, E.
    Hovey, E.
    Ellingson, B. M.
    Lwin, Z.
    NEURO-ONCOLOGY, 2018, 20 : 236 - 236
  • [22] Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET)
    Kulke, M. H.
    Frauenhoffer, C. S.
    Hooshmand, S. M.
    Ryan, D. P.
    Enzinger, P. C.
    Meyerhardt, J. A.
    Clark, J. W.
    Hornick, J.
    Fuchs, C. S.
    Redston, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825
    Zhou, Renke
    Scheurer, Michael
    Vera-Bolanos, Elizabeth
    Gilbert, Mark
    Bondy, Melissa
    Sulman, Eric
    Hilsenbeck, Sue
    Wendland, Merideth
    Brachman, David
    Roof, Kevin
    Komaki, Ritsuko
    Deutsch, Melvin
    Andrews, David
    Anderson, Bethany
    Lee, R. Jeffrey
    Pugh, Stephanie
    Armstrong, Terri
    NEURO-ONCOLOGY, 2014, 16
  • [24] Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
    Ruichao Chai
    Guanzhang Li
    Yuqing Liu
    Kenan Zhang
    Zheng Zhao
    Fan Wu
    Yuzhou Chang
    Bo Pang
    Jingjun Li
    Yangfang Li
    Tao Jiang
    Yongzhi Wang
    Cancer Biology & Medicine, 2021, 18 (01) : 271 - 285
  • [25] Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
    Chai, Ruichao
    Li, Guanzhang
    Liu, Yuqing
    Zhang, Kenan
    Zhao, Zheng
    Wu, Fan
    Chang, Yuzhou
    Pang, Bo
    Li, Jingjun
    Li, Yangfang
    Jiang, Tao
    Wang, Yongzhi
    CANCER BIOLOGY & MEDICINE, 2021, 18 (01) : 271 - +
  • [26] A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM)
    Mason, W. P.
    MacNeil, M.
    Easaw, J.
    McIntosh, L.
    Lwin, Z.
    Chen, E.
    Eisenhauer, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
    Brawanski, Konstantin R.
    Sprung, Susanne
    Freyschlag, Christian F.
    Hoeftberger, Romana
    Stroebel, Thomas
    Haybaeck, Johannes
    Thome, Claudius
    Manzl, Claudia
    Birkl-Toeglhofer, Anna M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [28] Long-term survival after glioblastoma multiforme treated by concurrent temozolomide (TMZ) and radiotherapy?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 51 - 52
  • [29] Long-term survival after glioblastoma multiforme, treated by concurrent temozolomide (TMZ) and radiotherapy?
    Micke, O.
    Schaefer, U.
    Schueller, P.
    Willich, N.
    NEURO-ONCOLOGY, 2006, 8 (04) : 311 - 311
  • [30] Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
    Antonopoulos, Markos
    Van Gool, Stefaan W.
    Dionysiou, Dimitra
    Graf, Norbert
    Stamatakos, Georgios
    ANTICANCER RESEARCH, 2019, 39 (04) : 2043 - 2051
12345